Indivior (INDV)
Develops monthly injectable and sublingual medicines for opioid use disorder.
Something off on this page? Send us feedback.
Develops and sells opioid-use-disorder treatments, led by monthly injectable SUBLOCADE and supported by sublingual buprenorphine medicines. Revenue is concentrated in the United States, while a pending merger with Supernus would replace the INDV listing after closing.
Develops and commercializes medicines for opioid use disorder, centered on SUBLOCADE, a monthly extended-release buprenorphine injection. SUBOXONE Film and SUBUTEX tablets provide sublingual buprenorphine options, while OPVEE overdose-reversal spray is distributed only on request after sales and marketing support ended.
Operates as one segment, pairing drug development and U.S.-focused commercialization with manufacturing and specialty distribution. The United States supplies most revenue; products also reach Canada, Australia, France, and Germany.
Results depend heavily on SUBLOCADE adoption, insurer and government reimbursement, regulated manufacturing, and competition from branded or generic treatments. An agreed all-stock merger with Supernus remains subject to stockholder and regulatory approvals; the combined company would trade as SUPN after closing.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 5, 2026 | Barclays | Reiterate | Rating: —Target: $46 | Target: $43 |
| Aug 4, 2026 | Craig-Hallum | Reiterate | Rating: —Target: $41 | Target: $53 |
| Jun 18, 2026 | Barclays | Target | Target: — | Target: $46 |
| Jan 20, 2026 | Northland Securities | Target | Target: $40 | Target: $50 |
| Jan 12, 2026 | H.C. Wainwright | Target | Target: $35 | Target: $48 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $222.0M · Total debt $509.0M · Total assets $1.23B · Shareholders' equity −$208.0M
- Revenue
- $343.0M
- Operating income
- $160.0M
- Net income
- $122.0M
HistoryDividendAnnual yieldUpcoming
| Institutions | ≈ 101.98% | 120.35M shares | |
|---|---|---|---|
| 348 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 11.01% | 12.99M shares | |
| 14 holders · as of Aug 27, 2026 | |||
| Adds to | 112.99% | ||
118.01M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 112.99%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 15.85% | 18.71M | as of Jun 30, 2026 |
Matthew SirovichInsider | 9.69% | 11.44M | filed Feb 14, 2024 |
Vanguard Portfolio Management LLCInstitution | 6.42% | 7.57M | as of Jun 30, 2026 |
Oaktree Capital Management LPInstitution | 5.19% | 6.13M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.66% | 5.50M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 27, 2026 | Woodrow D. Anderson | officer: Chief Accounting Officer | +1,500 | $35.69 |
| Aug 5, 2026 | Woodrow D. Anderson | officer: Chief Accounting Officer | +1,500 | $36.28 |
| Jul 10, 2026 | Christian Heidbreder | officer: Chief Scientific Officer | −18,586 | $41.14 |
| Jun 11, 2026 | Christian Heidbreder | officer: Chief Scientific Officer | −18,586 | $38.06 |
| Jun 8, 2026 | Ryan Preblick | officer: Chief Financial Officer | −36,000 | $37.70 |
- Alkermes
Monthly injectable OUD alternative through VIVITROL
- Teva (ADR)
Generic buprenorphine and UZEDY pressure legacy franchises
- Dr. Reddy's Laboratories (ADR)
Generic SUBOXONE Film challenger in the U.S.
- Emergent BioSolutions
NARCAN leads the overdose-reversal market against OPVEE
- Johnson & Johnson
INVEGA franchise overlaps de-emphasized PERSERIS
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Indivior | $36.12 | +1.67% | $4.43B | 12.7 | 8.0 | 3.3 | +13.6% |
| Alkermes | $43.72 | −1.04% | $7.41B | 115.4 | — | 4.4 | +27.0% |
| Teva (ADR) | $39.82 | −0.60% | $46.66B | 66.8 | 14.2 | 2.7 | −0.8% |
| Dr. Reddy's Laboratories (ADR) | $12.59 | +1.49% | $10.33B | 29.8 | 33.5 | 3.0 | −15.5% |
| Emergent BioSolutions | $6.71 | +2.44% | $338.0M | — | — | 0.4 | +66.3% |
| Johnson & Johnson | $267.17 | −0.85% | $649.40B | 31.2 | 22.5 | 6.6 | +6.6% |
| Median | 49.0 | 22.5 | 3.0 | +6.6% |